Skip to Main Content
Abbreviations
++

3D-CRT three-dimensional conformal radiotherapy

++

5-HIAA 5-hydroxyindoleacetic acid

++

5-HT3 5-hydroxytryptamine

++

AC Adriamycin and cyclophosphamide

++

ACC adrenal cortical carcinoma

++

ACIS automated cellular imaging system

++

ACTH adrenocorticotropic hormone

++

ADT androgen deprivation treatment

++

AFP α-fetoprotein

++

AJCC American Joint Committee on Cancer

++

ALPI Adjuvant Lung Cancer Project Italy

++

ANC absolute neutrophil count

++

ANITA Adjuvant Navelbine International Trialists Association

++

ASC active supportive care

++

ASCO American Society of Clinical Oncology

++

ASTRO American Society for Therapeutic Radiology and Oncology

++

AUC area under the curve

++ ++

BSO Bilateral salpingo-oophorectomy

++

CAB complete androgen blockade

++

CALGB Cancer and Leukaemia Group B

++ ++

CBR clinical benefit response

++

CEA carcinoembryonic antigen

++

CF cisplatin and 5-fluorouracil

++

CGA comprehensive geriatric assessment

++

CHOP cyclophosphamide, hydroxydaunomycin [doxorubicin], Oncovin [vincristine], and prednisone

++

CHR carboplatin hypersensitivity reaction

++ ++

CK cytokeratin

++ ++

CNS central nervous system

++

CSA cryosurgical ablation

++

CSF cerebrospinal fluid

++

CT computed tomography

++

CTZ chemoreceptor trigger zone

++

CVC central venous catheter

++

DMSO dimethylsulphoxide

++

DRE digital rectal examination

++ ++

EBRT external beam radiotherapy

++

ECF epirubicin, cisplatin and 5-fluorouracil

++

ECG electrocardiogram

++

ECOG PS Eastern Cooperative Oncology Group performance score

++

ECX epirubicin, cisplatin and capecitabine

++

EDTA ethylenediamine tetraacetic acid

++

EGFR epidermal growth factor receptor

++

ELND elective lymph node dissection

++ ++

EOF epirubicin, oxaliplatin and 5-fluorouracil

++

EORTC European Organisation for Research and Treatment of Cancer

++

EOX epirubicin, oxaliplatin and capecitabine

++ ++

ER oestrogen receptor

++

ERCP endoscopic retrograde cholangiopancreatography

++ ++

FAMTX 5-fluorouracil, doxorubicin and methotrexate

++

FE(50)C fluorouracil, epirubicin and cyclophosphamide

++

FIGO International Federation of Gynecology and Obstetrics

++

FISH fluorescence in-situ hybridization

++

FNA fine needle aspiration

++

G-CSF granulocyte-colony stimulating factor

++

GFR glomerular filtration rate

++

GIST gastrointestinal stromal tumour

++

GITSG Gastrointestinal Tumor Study Group

++

GM-CSFs granulocyte macrophage-colony stimulating factors

++

GP general practitioner

++

GTN gestational trophoblastic neoplasia

++

Hb haemoglobin

++

hCG human chorionic gonadotrophin

++

hCSF haemopoietic colony-stimulating factor

++

HD high dose intensity

++

HGG high-grade glioma

++

HIFU high frequency ultrasound

++

HR hazard ratio

++

IALT International Adjuvant Lung Cancer Trial

++

ICC interstitial cells of Cajal

++

IGCCC International Germ Cell Consensus Classification

++

IGCCCG International Germ Cell Cancer Collaborative Group

++

IL interleukin

++

IMRT intensity-modulated radiation therapy

++

IV intravenous

++

LACE Lung Adjuvant Cisplatin Evaluation

++

LDH lactate dehydrogenase

++

LVEF left ventricular ejection fraction

++

MASCC Multinational Association of Supportive Care in Cancer

++ ++

MRC Medical Research Council

++

MRCP magnetic resonance cholangiopancreatography

++

MRI magnetic resonance imaging

++

MSCC metastatic spinal cord compression

++ ++

MUGA multiple gated acquisition scan

++

NCCN National Comprehensive Cancer Network

++

NCIC National Cancer Institute of Canada

++

NHS National Health Service

++

NK-1 neurokinin-1

++

NPC nasopharyngeal carcinoma

++

NSABP National Surgical Adjuvant Breast and Bowel Project

++

NSAID non-steroidal anti-inflammatory drug

++

NSCLC non-small cell lung cancer

++

NSE neurone-specific enolase

++

NSGCT non-seminomatous germ cell tumour

++

OGD oesophagogastroduodenoscopy

++ ++

PD progressive disease

++

PDGFR platelet-derived growth factor receptor

++

PET positron emission tomography

++

PFS progression-free survival

++

PR progesterone receptor

++

PSA prostate-specific antigen

++

PSTT placental site trophoblastic tumour

++

PTCA percutaneous transhepatic cholangiography

++

RCC renal cell carcinoma

++

RECIST Response Evaluation Criteria in Solid Tumours

++

RFA radiofrequency ablation

++

rHuEPO recombinant human erythropoietin

++

RPLND retroperitoneal lymph node dissection

++

RR relative risk

++

RT radiotherapy

++

RTOG Radiation Therapy Oncology Group

++

SAGE serial analysis of gene expression

++

SLN sentinel lymph node

++

SMA smooth muscle actin

++

SNB sentinel node biopsy

++

SWOG Southwest Oncology Group

++ ++

TCC transitional cell carcinoma

++

TIA transient ischaemic attack

++

TIP paclitaxel, ifosfamide and cisplatin

++

TNF tumour necrosis factor

++

UFT uracil and tegafur

++

UKP unknown primary

++

VEGF vascular endothelial growth factor

++ ++

WCC white cell count

++

WLE wide local excision

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.